Stem cells from umbilical cord blood may help prevent finger and toe deformities caused by recessive dystrophic epidermolysis bullosa…
Articles by Margarida Maia, PhD
Researchers used a small molecule called M3814 for more accurate editing of genetic mutations causing recessive dystrophic epidermolysis bullosa…
A committee of the European Medicines Agency is recommending approving Vyjuvek (beremagene geperpavec), a gene therapy from Krystal Biotech,…
RLF-TD011, a spray of hypochlorous acid that Relief Therapeutics is developing to control infections in wounds of epidermolysis…
Children with dystrophic epidermolysis bullosa (DEB) in the U.S. are more likely to have visits to the emergency department…
Along with parents of children with epidermolysis bullosa (EB), adults with the rare disease in the Netherlands urged access…
The costs of an average hospital stay for a child with epidermolysis bullosa (EB) can exceed $110,000 and go…
The U.S. Food and Drug Administration (FDA) is pushing back its timeline for a decision on Abeona Therapeutics’ pz-cel (prademagene…
An inflammatory protein called interleukin (IL)-6 is found at higher levels in people with epidermolysis bullosa who have more…
A gene editing strategy corrected a disease-causing mutation in lab-grown cells derived from the skin of two individuals with recessive…
Tofacitinib, an oral anti-inflammatory medication, eased itching and reduced skin lesions in a young man with dystrophic epidermolysis bullosa…
Inflammation occurring early in the course of recessive dystrophic epidermolysis bullosa (RDEB) may create conditions for the disease to…